Abstract
Background
Vesnarinone Trial (VesT) was a three-armed, placebo-controlled, randomized clinical trial designed to study the effects of 30 mg or 60 mg/day vesnarinone. Certain contradictory results involving patient health-related quality-of-life (HRQOL) and overall survival (OS) have made a definitive and unified conclusion difficult.
Methods
To reconcile these findings, we have focused on the HRQOL-adjusted OS, commonly known as quality-adjusted life years (QALYs). Currently, analyses of QALYs incorporate a single HRQOL subscale. However, the VesT HRQOL instrument had two subscales: physical (PHYS) and emotional (EMOT). We have developed new ways to visualize and compare EMOT- and PHYS-adjusted OS.
Results
In each VesT arm, there was an increased probability of superior EMOT-adjusted OS, compared to PHYS-adjusted OS. The magnitude of these findings was comparable across trial arms. Despite inferior survival and superior EMOT and PHYS scores, the 60-mg/day arm presents similar EMOT- and PHYS-adjusted OS compared to the placebo arm.
Conclusions
We have provided a fresh perspective on the complex interactions between multiple HRQOL dimensions and OS. These novel methods address the burgeoning need for robust information on the interplay between OS and HRQOL from a patient, clinical care and public policy perspective.
Similar content being viewed by others
References
Spilker, B. (1996). Quality of life and pharmacoeconomics in clinical trials (2nd ed.). New York: Lippincott Williams & Williams.
Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2000) . SF-36 health survey: Manual and interpretation guide. Quality Metric Inc. Boston: Health Institute, New England Medical Center, 1993.
Parasuraman, S., Hudes, G., Levy, D., Strahs, A., Moore, L., DeMarinis, R., et al. (2007). Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 25(18S), 5049.
Kaarlola, A., Tallgren, M., & Pettil, V. (2006). Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Critical Care Medicine, 34(8), 2120–2126.
Muennig, P. A., & Gold, M. R. (2001). Using the years-of-healthy-life measure to calculate QALYs. American Journal of Preventive Medicine, 20(1), 35–39.
Sindelar, J. L., & Jofre-Bonet, M. (2004). Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal of Behavioral Health Services and Research, 31(3), 229–241.
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., et al. (1998). A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. The New England Journal of Medicine, 339, 1810–1816.
Rector, T. S., Kubo, S. H., & Cohn, J. H. (1993). Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. American Journal of Cardiology, 71, 1106–1107.
Torrance, G., & Feeny, D. (1989). Utilities and quality-adjusted life years. International Journal of Technology Assessment, 5, 559–575.
Glasziou, P. P., Cole, B. F., Gelber, R. D., Hilden, J., & Simes, R. J. (1998). Quality adjusted survival analysis with repeated quality of life measures. Statistics in Medicine, 17, 1215–1229.
Goldhirsch, A., Gelber, R., Simes, R., Glasziou, P., & Coates, A. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. Journal of Clinical Oncology, 7, 36–44.
Glasziou, P. P., Simes, R. J., Gelber, & R. D. (1990). Quality adjusted survival analysis. Statistics in Medicine, 9, 1259–1276.
Gelber, R. D., Cole, B. F., Gelber, S., & Goldhirsch, A. (1995). Comparing treatments using quality-adjusted survival: The Q-TWiST method. American Statistician, 49, 161–169.
Ahlstrom, A., Tallgren, M., Peltonen, S., Rasanen, P., & Pettila, V. (2005). Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Medicine, 31(9), 1222–1228.
Perkins, M., Howard, V., Wadley, V. G., Crowe, M., Safford, M. M., Haley, W. E., et al. (2013). Caregiving strain and all-cause mortality: evidence from the REGARDS study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 68(4), 504–512.
Nichol, M. B., Sengupta, N., & Globe, D. R. (2001). Evaluating quality-adjusted life years estimation of the Health Utility Index (HUI2) from the SF-36. Medical Decision Making, 21(2), 105–112.
Kamel, H., Johnston, S. C., Easton, J. D., & Kim, A. S. (2012). Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke, 43(3), 881–883.
Rogers, J. G., Bostic, R. R., Tong, K. B., Adamson, R., Russo, M., & Slaughter, M. S. (2012). Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circulation: Heart Failure, 5(1), 10–16.
Saarni, S., Suvisaari, J., Sintonen, H., Koskinen, S., Harkanen, T., & Lonngvist, J. (2007). The health-related quality of life impact of chronic conditions varied with age in general population. Journal of Clinical Epidemiology, 60(12), 1288–1297.
Ferguson, N. D., Scales, D. C., & Pinto, R., et al. (2013). Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical trials. American Journal of Respiratory and Critical Care Medicine, 187(3), 256–261.
Lin, D. Y., Sun, W., & Ying, Z. (1999). Nonparametric estimation of the gap time distributions for serial events with censored data. Biometrika, 86, 59–70.
Zhao, H., & Tsiatis, A. A. (1997). A consistent estimator for the distribution of quality adjusted survival time. Biometrika, 84, 339–348.
Gill, R. D. (1983). Large sample behaviour of the product-limit estimator on the whole line. Annals of Statistics, 11, 49–58.
Andrei, A. -C., & Murray, S. (2006). Estimating the quality-of-life-adjusted gap time distribution of successive events subject to censoring. Biometrika, 93(2), 343–355.
Acknowledgments
The authors thank the University of Wisconsin SDAC for providing the VesT dataset.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Commonly, individual \(i=1,\ldots, n\) time to event T i is subject to independent right-censoring by C i , hence the follow-up time \(\widetilde{T}_i={\text{minimum}}(T_ i, C_i)\) and the censoring indicator \(\Updelta_i=I(T_i \leq C_i)\). Both T i and C i are assumed to be continuous. HRQOL is measured using a preference-based questionnaire with several subscales. For simplicity, assume it only has two subscales, p = 1, 2. HRQOL on the pth scale, is quantified by a continuous-time stochastic process \(V^{(p)}(\cdot)\), with state space \(\mathcal{S}_p=\{0,1,\ldots, S_p\}\). Assume that the health states in \(\mathcal{S}_p\) are ordered increasingly, “0” being the worst and “S p ” the best state. For each individual \(i=1,\ldots, n\), assume that \(V_{i}^{(p)}(\cdot)\) and C i are independent and let a non-decreasing, known function \(Q^{(p)}(\cdot)\) assign utilities between 0 (state “0”) and 1 (state “S p ”) to each state in \(\mathcal{S}_p\). For example, one could think of \(V^{(1)}(\cdot)\) and \(V^{(2)}(\cdot)\) as being the emotional and physical health subscales in the VesT example. When using a generic pair \(\{V(\cdot),Q(\cdot)\}\), the HRQOL-adjusted lifetime is defined as
and its observed version is
Since T is adjusted on two different HRQOL scales, the resulting Q (1) T and Q (2) T are correlated. Their joint distribution is necessary to perform testing for significance.
Assume the existence of a constant L > 0 such that P(T < L) = 1 and P(C > L) > 0. A technical assumption, first, we estimate the joint distribution of Q (1) T and Q (2) T, namely F 1,2(q 1, q 2) = P(Q (1) T ≤ q 1, Q (2) T ≤ q 2). Define H 1,2(q 1, q 2) as P(Q (1) T > q 1, Q (2) T > q 2) and note that
Thus, to estimate \(F_{1,2}(\cdot,\cdot)\) it suffices to estimate \(H_{1,2}(\cdot,\cdot)\). In the absence of censoring and based on a sample of size n, H 1,2(q 1, q 2) can be estimated by the empirical mean of the corresponding indicators of interest,
However, when censoring is present, define \(m^{(p)}_i(t)={\text {infimum}} \left[s \geq 0 ; \int_{0}^{s}Q^{(p)}\{V^{(p)}_{i}(u)\}{\text{d}}u \geq t \right]\) and D (p) i (t) = m (p) i (t) ∧ T i , for p = 1,2 and \(i=1,\ldots, n\). By convention, D (p) i (0) = 0. This expression states that D (p) i (t) marks the first time when the ith individual has accumulated at least t HRQOL-adjusted lifetime on the \(Q^{(p)}(\cdot)\) scale. Should this not happen until time T i , then D (p) i (t) is assigned the value T i . The key to producing a consistent estimator for the quantity of interest is to note that if \(\widetilde{Q^{(p)}T_i} > q_p\), then Q (p) T i > q p and censoring time C i does not occur prior to D (p) i (q p ).
Consequently, if A (p) i (q p ) = I{Q (p) T i > q p , C i > D (p) i (q p )} and \(B^{(p)}_i(q_p)=I\{\widetilde{Q^{(p)}T}_i > q_p \}\), then A (p) i (q p ) = B (p) i (q p ), where p = 1,2. Here, \(I\{ \cdot \}\) represents the indicator function. Define D (1,2) i (q 1, q 2) to be the maximum of D (1) i (q 1) and D (2) i (q 2). An inverse probability-of-censoring weighted estimator becomes available after assessing when the indicator functions involved are completely observed. Further, should G(u) = P(C > u) be known
would represent an unbiased estimator for H 1,2(q 1, q 2).
This assertion is true because
However, G(u) being unknown, it is estimated by the Kaplan–Meier estimator \(\widehat{G}(u)\) of the censoring time survival function computed using \(\{(\widetilde{T}_i,1-\Updelta_i);i=1,\ldots, n\}.\)
Estimator consistency
A consistent estimator for H 1,2(q 1, q 2) is
from which a consistent estimator \(\widehat{F}_{1,2}(q_1,q_2)\) of F 1,2(q 1, q 2) becomes immediately available. Consistency of H 1,2(q 1, q 2) is shown using arguments along the lines of [21] and [22]. Note that-1
The expression in (1) is a sum of zero-mean i.i.d. terms, so it converges to zero in probability. In addition, D (1,2) i (q 1, q 2) < L < τ C : = sup{t;G(t) > 0} and \(\widehat{G}\) converges uniformly in probability to G on [0, τ C ). The term in (2) is bounded from above, in absolute value, by
so it converges to zero, in probability. This shows that \(\widehat{H}_{1,2}(\cdot,\cdot)\) is a consistent estimator of \(H_{1,2}(\cdot,\cdot)\); hence, an estimator for \(F_{1,2}(\cdot,\cdot)\) can be derived easily.
Limiting distribution results
Let \(M^{c}(u)=I\{C \leq u, C \leq T)\}- \int_0^{u}I(\widetilde{T} \geq s){\text{d}}\Uplambda^{c}(s)\), where \(\Uplambda^{c}(s)=exp\{-G(s)\}\) represents the cumulative hazard function of the censoring distribution. Using Lemma 2.4 in [23], it follows that for all \(t\leq {\text{max}}\{\widetilde{T}_{j};j=1,\ldots, n\}\), we have that
When t = D (1,2) i (q 1, q 2) in the previous formula, one obtains that
Note that \(W_{1,2}(q_1,q_2):=n^{1/2} \{\widehat{H}_{1,2}(q_1,q_2)-H_{1,2}(q_1,q_2)\} =n^{1/2}\{\widetilde{H}_{1,2}(q_1,q_2)-H_{1,2}(q_1,q_2)\} +n^{1/2}\{\widehat{H}_{1,2}(q_1,q_2)-\widetilde{H}_{1,2}(q_1,q_2)\}\)
Because
it follows that the second term in (3) can be written as
where
Then, one can further write
Consequently, the asymptotic covariance of W 1,2(q 1, q 2) and W 1,2(r 1, r 2) is equal to
Note that the expression in (4) is equal to
Terms (4) and (5) are both equal to
using arguments as in [24]. Standard results for stochastic integrals with respect to martingales lead to the fact that the expression in (6) is equal to
By applying the multivariate central limit theorem, it follows that \(W_{1,2}(\cdot,\cdot)\) converges in finite-dimensional distribution to a 4-variate zero-mean Gaussian process whose covariance function is equal to
Recall that F 1,2(q 1, q 2) = H 1,2(0, 0) −H 1,2(q 1, 0) − H 1,2(0, q 2) + H 1,2(q 1, q 2). Using the previous findings, it follows that \(\sqrt{n}\{\widehat{F}_{1,2}(q_1,q_2)-F_{1,2}(q_1,q_2)\}\) converges in finite-dimensional distribution to a 4-variate zero-mean Gaussian process with covariance function
Define R 1,2(q 1, q 2, u) = J 1,2(0, 0, u) − J 1,2(q 1, 0, u) − J 1,2(0, q 2, u) + J 1,2(q 1, q 2, u) and
After involved, but direct, computations, it follows that σ F_1,2(q 1, q 2;r 1, r 2) is equal to
Variance estimation
Following standard arguments, the cumulative hazard \(\Uplambda^{c}(t)\) of the censoring distribution is estimated by the Nelson–Aalen estimator
The value of \(P(\widetilde{T} \geq u)\) can be consistently estimated by \(n^{-1} \sum\nolimits_{i=1}^{n} I(\widetilde{T}_{i}\geq u)\), while an estimator for J 1,2(q 1, q 2, u) is given by
Furthermore, \(\varvec{\Upgamma}_{1,2}(q_1,q_2)\) and R 1,2(q 1, q 2, u) are estimated by
and \({\bf \widehat{R}}_{1,2}(q_1,q_2,u)= \hat{J}_{1,2}(0,0,u)- \hat{J}_{1,2}(q_1,0,u)- \hat{J}_{1,2}(0,q_2,u)+ \hat{J}_{1,2}(q_1,q_2,u)\), respectively.
In conclusion,
and
are consistent estimators of σ H_1,2(q 1, q 2;r 1, r 2) and σ F_1,2(q 1, q 2;r 1, r 2), respectively.
Confidence intervals
Based on these derivations, a 100 × (1 − α)-level confidence interval for TOF(t) is
\([\widehat{TOF}(t)-z_{1-\alpha} \sqrt{\widehat{\sigma}_{H_{1,2}}(t,0;0,t)/n}, \widehat{TOF}(t)+z_{1-\alpha} \sqrt{\widehat{\sigma}_{H_{1,2}}(t,0;0,t)/n}]\), where n is the group size and z 1-α is the upper α th quantile of the N(0, 1) distribution.
We now focus on the two-group setting. Let n 1 and n 2 be the sample sizes of the two groups, respectively. A 100 × (1 − α)-level confidence interval for TOFgroup 1(t) − TOFgroup 2(t) is
Rights and permissions
About this article
Cite this article
Andrei, AC., Grady, K.L. Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach. Qual Life Res 23, 1411–1419 (2014). https://doi.org/10.1007/s11136-013-0608-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-013-0608-1